A former regional account manager for TAP Pharmaceutical Products, Inc., has been convicted for making false declarations to a U.S. Grand Jury. The conviction of Joanne Richardson is related to her role in illegal marketing practices concerning TAP's LHRH agonist leuprolide acetate (Lupron).
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.